Preparing for the Next Biotech Growth Cycle with BBH: A Guide to BBH vs. IBB

The biotech industry is gaining momentum due to innovations like AI and CRISPR gene editing, making it a promising area for investment. Biotech companies have shown significant growth potential, and investors can prepare for the next growth cycle by investing in biotech exchange-traded funds (ETFs) such as BBH.

The biotech industry is witnessing significant growth, driven by innovations such as CRISPR gene editing and artificial intelligence (AI). These advancements are making the industry a promising area for investment, particularly for those looking to capitalize on the next growth cycle. One of the key areas of focus for investors is CRISPR-based gene editing, which has shown immense potential in treating genetic disorders and enhancing agricultural productivity.

According to Nova One Advisor [1], the global CRISPR-based gene editing market size is expected to reach USD 24.37 billion by 2034, increasing from USD 7.06 billion in 2025, with a healthy compound annual growth rate (CAGR) of 14.76% from 2025 to 2034. This growth is attributed to the technology's simplicity, precision, high efficiency, and multiplexing capability, which offer significant advantages over older genome editing techniques like zinc finger nucleases (ZFNs) and TALENs.

The market is dominated by North America, which holds the largest revenue share of 41.88% in 2024, driven by strong government funding for advanced research and development. The Asia Pacific region, however, is anticipated to witness the fastest CAGR of 16.96% from 2025 to 2034, indicating a robust growth trajectory. The products segment, which includes CRISPR kits and reagents, led the market with the largest revenue share of 74.18% in 2024, while the services segment is expected to grow significantly during the forecast period.

CRISPR gene editing has shown great promise in treating genetic disorders, with recent advancements including the conditional marketing authorization for CASGEVY by Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics for sickle cell disease and transfusion-dependent beta thalassemia [2]. Additionally, the Chan Zuckerberg Initiative and the Innovative Genomics Institute announced the funding of the Center for Pediatric CRISPR Cures, which aims to advance cures for severe pediatric genetic diseases [3].

Investors can prepare for the next growth cycle by considering investments in biotech exchange-traded funds (ETFs) such as BBH, which offer exposure to a diversified portfolio of biotech companies. These ETFs provide a convenient way to invest in the biotech industry without the need to select individual stocks.

References:
[1] https://www.biospace.com/press-releases/crispr-based-gene-editing-market-size-to-reach-usd-24-37-billion-by-2034
[2] https://www.biospace.com/press-releases/crispr-based-gene-editing-market-size-to-reach-usd-24-37-billion-by-2034
[3] https://www.biospace.com/press-releases/crispr-based-gene-editing-market-size-to-reach-usd-24-37-billion-by-2034